PasiAnteroJanneMDMD, PhD

Oncology • Boston, MA

Associate Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Janne is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Janne's full profile

Already have an account?

Office
44 Binney St
# Dana
Boston, MA 02115
Phone+1 617-632-6049

Fax+1 617-632-5786

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2001
Brigham and Women's HospitalInternship, Internal Medicine, 1996 - 1997
Perelman School of Medicine at the University of PennsylvaniaClass of 1996

Certifications & Licensure

MA State Medical License 1998 - 2024
NH State Medical License 2024 - 2024
RI State Medical License 2020 - 2020

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Elected Member The American Society for Clinical Investigation, 2008

Clinical Trials

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. Start of enrollment: 2004 Oct 01
Completed
Phase 2
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer Start of enrollment: 2005 Aug 15
Completed
Phase 2
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients Start of enrollment: 2003 Feb 01
Completed
Phase 2
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma Start of enrollment: 2004 Feb 01
Completed
Phase 2
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung Start of enrollment: 2004 Nov 01
Completed
Phase 2
Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer Start of enrollment: 2005 Jun 01
Completed
Phase 2
Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer Start of enrollment: 2005 Nov 01
Completed
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. Start of enrollment: 2012 Dec 18
Completed
Phase 2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Start of enrollment: 2014 Sep 26
Recruiting
Not Applicable
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Start of enrollment: 2018 Jan 31
Active, not recruiting
Phase 2
Osimertinib In EGFR Mutant Lung Cancer Start of enrollment: 2018 Aug 13
Recruiting
Phase 2
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) Start of enrollment: 2019 Jul 09
Active, not recruiting
Phase 1, Phase 2
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations Start of enrollment: 2020 Jan 10
Active, not recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

2 citations
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada, Jessica K Lee
Cancer Discovery. 2024-08-02
24 citations
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
Lars D Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut
Cancer Discovery. 2023-11-01
3 citations
Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study.
Leou Ismael Banla, Alice Tzeng, John P Baillieul, Melin J Kandekhar, Kelly J Fitzgerald
JTO Clinical and Research Reports. 2023-10-01

Journal Articles

Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid Tumors
Jeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature

Lectures

Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.
2019 ASCO Annual Meeting - 6/1/2019
Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.
2019 ASCO Annual Meeting - 6/1/2019
Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Erasca Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven CancersJune 2nd, 2022
Takeda Pharmaceutical : EXKIVITY (Mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLCSeptember 20th, 2021
WCLC 2021: KRAS Drugs May Do Best in Tough SubtypeFebruary 2nd, 2021
Join now to see all

Grant Support

The Use Of Whole-Exome Sequencing To Guide The Care Of Cancer PatientsNational Human Genome Research Institute2012
EML4-ALK: A Potential Therapeutic Target In Lung CancerNational Cancer Institute2009–2012
Drug Resistance In Lung CancerNational Cancer Institute2008–2011
Mechanisms Of Acquired Resistance To Egfr-Targeted AgentsNational Cancer Institute2008–2009